A-Alpha Bio Raises $22.4M in Series A2 to Scale Protein-Protein Interaction Data Platforms and Accelerate Internal Pipeline Development

We’re excited to announce that A-Alpha Bio has raised an additional $22.4M in Series A2 funding to advance our platforms and accelerate internal pipeline development.

The oversubscribed round was led by previous investor Perceptive Advisors Xontogeny Ventures, with strong support from Madrona and other existing investors. We’re thrilled to have Breakout Ventures join the round, bringing a depth of experience in building drug discovery and data-driven synthetic biology platform companies. As a result, we are very pleased to welcome Managing Director Lindy Morris Fishburne as a Board Observer for A-Alpha Bio! 

The strong support from new and existing investors is a powerful endorsement of our team’s rapid progress and growth – including the demonstrated versatility of our platforms across high-value applications, recent partnerships with industry-leading pharmaceutical companies, and early success with internal programs in biologics and molecular glues.

Looking ahead, there are many exciting things on the horizon. From all of us at A-Alpha Bio, we thank you for your continued support in our mission to improve human health through the measurement and engineering of protein-protein interactions.

You can read our coverage in the Timmerman Report here.

And read more about the raise in our press release here.